- Austria / Österreich
- Bosnia and Herzegovina / Босна и Херцеговина
- Bulgaria / България
- Croatia / Hrvatska
- Czech Republic & Slovakia / Česká republika & Slovensko
- France / France
- Germany / Deutschland
- Greece / ΕΛΛΑΔΑ
- Italy / Italia
- Netherlands / Nederland
- Nordic / Nordic
- Poland / Polska
- Portugal / Portugal
- Romania & Moldova / România & Moldova
- Slovenia / Slovenija
- Serbia & Montenegro / Србија и Црна Гора
- Spain / España
- Switzerland / Schweiz
- Turkey / Türkiye
- UK & Ireland / UK & Ireland
Today, the United States Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have issued a statement recommending a pause in the use of the Johnson & Johnson COVID 19 vaccine out of an abundance of caution.
After administering more than 6.8 million doses of the Johnson & Johnson vaccine (as of April 12), the U.S. CDC and FDA are currently reviewing six reported cases of a rare and severe type of blood clot in individuals who had received the J&J vaccine. All six cases occurred among women between 18 and 48 years, and symptoms occurred 6 to 13 days after receiving the vaccine.
These cases presented with a rare type of blood clot called cerebral venous sinus thrombosis (CVST) combined with low levels of blood platelets (thrombocytopenia). Treatment of this specific type of blood clot differs from the typically administered treatment (heparin, an anticoagulant drug). However, heparin administration may be dangerous in the current situation. Therefore, alternative treatments need to be given.
CDC and FDA will review these cases to assess their potential significance, and until that process is over, they are recommending a pause in the J & J vaccine use out of an abundance of caution.
CDC and FDA have asked the J & J vaccinees to report to their healthcare providers if they develop severe headaches, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination. Healthcare providers will in turn report the adverse events to the Vaccine Adverse Event Reporting System (VAERS).
Ref: Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine
Link: https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html
Tags:
Wed. 24 April 2024
5:30 pm IST (New Delhi)
YITI Lounge: Navigating modern implant dentistry—from prosthetic planning to digital verification, are we there yet?
Wed. 24 April 2024
10:30 pm IST (New Delhi)
Advanced techniques in peri-implant tissue augmentation and maintenance
Fri. 26 April 2024
9:30 pm IST (New Delhi)
How you can access data-driven decision making
Mon. 29 April 2024
10:00 pm IST (New Delhi)
Root caries: The challenge in today’s cariology
Tue. 30 April 2024
10:30 pm IST (New Delhi)
Neodent Discovery: Neoarch Guided Surgery—from simple to complex cases
Wed. 8 May 2024
5:30 am IST (New Delhi)
You got this! Diagnosis and management of common oral lesions
Fri. 10 May 2024
5:30 am IST (New Delhi)
To post a reply please login or register